Organizations should improve the options available to providers who choose to override drug-drug interaction (DDI) alerts. We found wide variability in override reasons and many opportunities to improve alerts.
Currently, there is no standard of care covering which DDI alerts to implement or how to display them to providers. Opportunities to improve DDI alerting include using differential displays based on DDI severity, establishing improved lists of clinically significant DDIs, and thoroughly reviewing organizational implementation decisions regarding DDIs.
OBJECTIVE: To measure performance by eligible health care providers on CMS’s meaningful use measures. DATA SOURCE: Medicare Electronic Health Record Incentive Program Eligible Professionals Public Use File (PUF), which contains data on meaningful use attestations by 237,267 eligible providers through May 31, 2013. STUDY DESIGN: Cross-sectional analysis of the 15 […]
